Rapid Micro Biosystems, Inc. RPID PHARMA
Company Overview
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquated, manual microbial quality control (MQC), testing workflows for therapeutic modalities, such as biologics and cell and gene therapies, vaccines, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Why Investors Should Care
Revenue has grown at a 20.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $33.59M (+19.7% YoY); net profit $-47.12M.
- Trailing 12 Months Year-on-year growth — revenue +10.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.22% |
| 1 Year: | 10.90% |
Stock Price Performance
| 1 Year: | -58.08% |
| 6 Months: | -70.95% |
| 3 Months: | -38.69% |
| 1 Month: | -29.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)19.20 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.2% over 5 years.
CONS
- Trading 73.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 19 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RPID Rapid Micro Biosystems, Inc. PHARMA | 1.22 | -1.10 | $55.71M | 0.00% | -84.08% | -141.65% | 20.22% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 2.59M | 5.25M | 5.00M | 6.13M | 6.90M | 4.16M | 3.86M | 4.74M | 5.04M | 5.00M | 6.14M | 5.61M | 6.62M | 7.60M | 7.21M | 7.26M | 7.84M | 11.28M | 8.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.80M | 6.99M | 7.14M | 11.61M | 7.63M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 404.00K | 275.00K | 696.00K | -328.00K | 371.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.06M | 12.42M | 12.07M | 11.88M | 14.22M |
| Operating Income | - | -6.01M | -7.58M | -9.69M | -10.86M | -12.12M | -15.00M | -14.07M | -16.89M | -14.87M | -15.05M | -14.45M | -14.27M | -13.38M | -12.04M | -11.66M | -12.15M | -11.37M | -12.21M | -13.85M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -10.40M | -11.34M | -10.30M | -11.02M | -12.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00K | - | 393.00K | 673.00K | 639.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -11.26M | -11.85M | -11.50M | -12.48M | -14.27M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00K | 11.00K | 8.00K | 14.00K | 8.00K |
| Net Income | -8.01M | -9.27M | -8.46M | -22.10M | -11.83M | -24.99M | -14.93M | -13.09M | -16.34M | -13.89M | -14.02M | -13.39M | -13.32M | -12.58M | -11.32M | -11.26M | -11.86M | -11.51M | -12.50M | -14.28M |
| Diluted EPS | - | -31.93 | -30.08 | -37.89 | -20.01 | -0.71 | -0.35 | -0.31 | -0.38 | -0.32 | -0.33 | -0.31 | -0.31 | -0.29 | -0.26 | -0.26 | -0.27 | -0.26 | -0.28 | -0.31 |
| R&D Expense | - | 1.24M | 2.22M | 2.15M | 2.34M | 2.44M | 3.52M | 2.96M | 2.97M | 3.15M | 3.23M | 3.12M | 3.84M | 3.74M | 3.61M | 3.62M | 3.23M | 3.53M | - | 3.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 16.08M | - | 17.13M | 22.52M | 28.05M | 33.59M |
| Cost of Revenue | - | - | 25.67M | 28.00M | 28.16M | 32.54M |
| Gross Profit | - | - | -8.54M | -5.49M | -109.00K | 1.05M |
| Operating Expenses | - | - | 54.68M | 51.08M | 49.81M | 48.44M |
| Operating Income | -30.54M | - | -63.22M | -56.56M | -49.92M | -47.39M |
| EBITDA | - | - | -60.38M | -53.46M | -43.47M | -42.74M |
| Interest Expense | - | 2.65M | - | - | 40.00K | 1.09M |
| Pretax Income | - | - | -61.38M | -52.44M | -46.87M | -47.08M |
| Tax Provision | - | - | -576.00K | 31.00K | 22.00K | 40.00K |
| Net Income | -37.08M | - | -60.81M | -52.47M | -46.89M | -47.12M |
| Diluted EPS | -126.11 | - | -1.43 | -1.22 | -1.08 | -1.05 |
| R&D Expense | 6.53M | 9.78M | 12.87M | 12.82M | 14.60M | 13.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 70.00M | - | 190.65M | 143.45M | 98.17M | 74.85M |
| Current Assets | - | - | - | 138.58M | 120.42M | 80.92M | 61.17M |
| Cash & Equivalents | - | 30.08M | - | 27.06M | 24.29M | 16.91M | 20.03M |
| Inventory | - | - | - | 21.19M | 19.96M | 20.20M | 17.59M |
| Receivables | - | - | - | 5.37M | 5.53M | 7.52M | 3.13M |
| Total Liabilities | - | 45.18M | - | 26.48M | 25.46M | 22.82M | 41.65M |
| Current Liabilities | - | 15.54M | - | 19.05M | 18.99M | 17.57M | 18.49M |
| Long Term Debt | - | 24.81M | - | - | - | - | 18.90M |
| Total Debt | - | - | - | 7.97M | 7.35M | 6.17M | 23.87M |
| Total Equity | -82.58M | -127.01M | - | 164.17M | 117.99M | 75.35M | 33.21M |
| Shares Outstanding | - | - | - | 42.09M | 42.41M | 43.04M | 44.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -31.00M | - | -58.55M | -45.08M | -44.15M | -31.06M |
| Investing Cash Flow | -15.67M | - | -93.47M | 42.15M | 36.66M | 14.33M |
| Financing Cash Flow | 64.23M | - | 693.00K | 149.00K | 203.00K | 19.77M |
| Capital Expenditure | -690.00K | - | -6.74M | -1.84M | -1.36M | -850.00K |
| Free Cash Flow | -31.69M | - | -65.29M | -46.93M | -45.52M | -31.91M |
| Net Change in Cash | - | - | -151.32M | -2.78M | -7.29M | 3.04M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | -49.8% | -24.4% | -0.4% | 3.1% |
| Operating Margin % | -190.0% | - | -369.0% | -251.2% | -178.0% | -141.1% |
| Net Margin % | -230.6% | - | -354.9% | -233.0% | -167.2% | -140.3% |
| ROE % | 29.2% | - | -37.0% | -44.5% | -62.2% | -141.9% |
| ROCE % | -56.1% | - | -36.8% | -45.4% | -61.9% | -84.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Investors, LLC | 18.47% | 8.43M | $9.45M |
| 2 | Armistice Capital, LLC | 7.29% | 3.33M | $3.73M |
| 3 | ABG-WTT Global Life Science Capital Partners GP Ltd | 4.05% | 1.85M | $2.07M |
| 4 | Vanguard Capital Management LLC | 2.15% | 982.03K | $1.10M |
| 5 | Evernest Financial Advisors, LLC | 1.11% | 506.00K | $566.72K |
| 6 | Advent International LP | 0.83% | 379.79K | $425.37K |
| 7 | Essex Investment Management Co LLC | 0.79% | 362.70K | $406.22K |
| 8 | Millennium Management Llc | 0.52% | 236.60K | $264.99K |
| 9 | Geode Capital Management, LLC | 0.50% | 228.04K | $255.41K |
| 10 | Renaissance Technologies, LLC | 0.46% | 212.10K | $237.55K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RPID
A live webcast is planned for Sept. 24 as Rapid Micro Biosystems presents to investors - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPbzRhdzktdFNxZG15V0x1ellTWEdIR2VNVndVMnctdER2TG5WZC1WLWJoNjI3aDhGZ3lSdnBoN0RsUnJscXphYzBybldLYkU2MDZKSWY0dGRhenNESXpWWUZqTG55WVNBU0xmZk55M2F0cjRVc2k0S2IxUWNobDRJZWdOSWYwUkF6cGJQaD…
After Plunging 33.7% in 4 Weeks, Here's Why the Trend Might Reverse for Rapid Micro Biosystems (RPID) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNd3lTeUhpQ2tUV2dtNGZuS1BGUldxQnEtOWYySmlBZDhhQ2p5MWR2bWU4RVJLQmZxekpYR0FDcXFmY2hqOUJCNTZsY2swZ2FEekJuZC1RbDFVX3JqbHpIUElEUE1majFGbTFxZjdxdUlsOGNVaUhZNU5NVXZMaGphenZaZmtkeVhHQ2xxRl…
Rapid Micro Biosystems Inc (NASDAQ: RPID) Share Price, RPID Stock News, RPID Share Price & Updates - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE8zcWZiUlA2XzhIaXB6d3RvdzNZandvZklpTHlMNi0yT25qQy1sTlgxQl9MVm9wVFo3a0xfdzhVVHIzY1dVYVh5RjNSSUxIM3Bu?oc=5" target="_blank">Rapid Micro Biosystems Inc (NASDAQ: RPID) Share Price, RPID…
Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPdVE3RVFXVnJfQjVtQjNOQW40anNYczBNcXNjMTByYjRBbnluMkdXdlhWeGNxNHl4cDNTRUlSbDhSbjQ3TGNLWlhiRk9SUmtpZWp0WjFsckZtR19CVkF1TGVNdGliOHhiUUhCSnRqYjFsWmxOaU1ZeVloMVl5dm9QVFNQRjV3X3R6eEVVaj…
RPID Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1mNjZyV28xUElvZUh3ODJ1UmpaVEhnaVdBRUt2WEdRZEJyb2lhVWZfdHZUUkN5aTVuc3B2c0I3SDFBOHhPRHc1Z3RSeVRrRzFXbnVJOWpSaDNyTVNjcWlZTF9vd0g0bHd5ZkpybkJMemNPckk5aW1wTndn?oc=5" target="_blank">RPI…
$RPID stock is down 20% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPSkdZTEdublg0ZGhfa0xTUmZsX2FSaG95QXZTWW1qMW1ZU3hZcEZxVnBSWHpveVlETXNGbmI4OEpNWkl5ZHoxZXAzUkJfV25Ncnl5V191RV9jckNlTm9oQ3lxdGNXSjBlTWg5OVZ1TDByRk1JeWVVOHNIcFNHeEZEQVhyWF9CeDBKS2JGdE…
RPID — Frequently Asked Questions
What is the current share price of Rapid Micro Biosystems, Inc. (RPID)?
As of 2026-09-19 21:16 PDT, Rapid Micro Biosystems, Inc. (RPID) trades at $1.22 on NasdaqCM. Its 52-week range is $1.22 to $4.68.
What is the market capitalisation of RPID?
Rapid Micro Biosystems, Inc. (RPID) has a market capitalisation of $55.71M on NasdaqCM.
What is the P/E ratio of RPID?
RPID trades at a trailing price-to-earnings (P/E) ratio of -1.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.15.
What is the return on equity (ROE) of RPID?
RPID has a return on equity (ROE) of -141.65%. Its return on capital employed (ROCE) is -84.08%.
Is RPID a good stock to buy?
This page provides a data-driven analysis of Rapid Micro Biosystems, Inc. (RPID), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.